In Q4 2024, we partnered with an orthopedic medical device startup in the joint reconstructi...
In Q4 2024, we partnered with an orthopedic medical device startup in the joint reconstructi...
The ChallengeA small molecule CDMO faced over a 70% turnover rate, struggled to meet product...
A cardiovascular medical device company (a publicly traded company generating around $300 mi...
Learn how Barrington James successfully assembled a dedicated commercial team for a mid-size...
A mid-sized medical device company, specializing in cardiovascular and hematology faced a re...
We delivered market insights and a VP Finance shortlist, supporting a Swiss oncology biotech...
Explore how Barrington James effectively filled urgent Pharmacovigilance leadership roles fo...
We placed 135 hires in 4 years, enabling In Vivo department growth and meeting preclinical d...